Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 14 of 123 for:    hypertension "vitamin d"

Effect of Vitamin D Supplementation on Blood Pressure in Elderly People

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02047799
Recruitment Status : Completed
First Posted : January 28, 2014
Last Update Posted : November 13, 2017
Sponsor:
Information provided by (Responsible Party):
Universidad de Colima

Brief Summary:
The prevalence and incidence of cardiovascular disease (such as Hypertension) increases exponentially with age (McDermott, 2007;) These diseases account for 30% of the global mortality (WHO, 2011). Vitamin D (VD) insufficiency affects as many as half of otherwise healthy adults in developed countries (Holick, 2007). VD is implicated in the control of blood pressure (BP) through inhibition of the renin-angiotensin system (Yamshchikov, 2009), although the role of VD supplementation for prevention and treatment of the HTA is controversial.The purpose of this study was to investigate if VD supplement in elderly people reduces the levels of BP.

Condition or disease Intervention/treatment Phase
High Blood Pressure Dietary Supplement: Calcitriol Dietary Supplement: Control Phase 2

Detailed Description:

Study population Adults aged ≥ 60 years with essential hypertension were recruited through nursing homes and physical activity groups in the state of Colima, México. 45 subjects were assessed for eligibility at our out-patient clinic. We excluded subjects with impaired renal or hepatic function; also subjects who had been treated with vitamin D within the last three months.

None were on hormone replacement therapy, but we included subjects on anti-hypertensive for more than 10 years and the dosages were unchanged during the study. Before randomization, two subjects withdrew the informed consent because of personal reasons, and two subjects were excluded due to the diagnosis of severe hypertension.

Design The design was a double-blind, placebo controlled randomized clinical trial. The participants were randomly assigned using a computer-generated randomization code into two groups: group 1 (calcitriol group)with 22 subjects whom were enrolled for 6 weeks of treatment with a daily dose of 1000 IU of cholecalciferol (administered as 1 capsule of 25 μg each) and group 2 with 23 subjects (control group) whom received a similar placebo tablet for also 6 weeks.

During treatment, nine subjects (20%) left the trial due to personal reasons. All patients provided written informed consent. The study was conducted in accordance with the Declaration of Helsinki II and the guidance on Good Clinical Practice (GCP). Approval was obtained from the bioethics committee of the Faculty of Medicine from the University of Colima (FM014/2012).

Measurement At the screening visit prior to randomization, subjects had a routine clinical examination and data concerning medical history. BP was measured 3 consecutive days at the same time, using a kit integrated aneroid sphygmomanometer with stethoscope (medimetrics 5769) with the patient seated and with at least 5 min rest. The subjects with average BP >140/90 mm Hg were included in the study.

Once enrolled in the study groups, anthropometrics measurements were collected. The measurements performed were weight and height with light clothing and no shoes, and the indicator body mass index (kg/m2) was calculated. For the determination of serum 25(OH)D,two blood samples were collected in the morning after an overnight fast of minimum 8 h on the day of the randomization and at the end of the study.

The patients attended control visits every week for safety measures, adverse event registration and assessment of compliance.Returned pills were counted at each visit, and compliance was calculated as the percentage of used pills compared to the expected number.

Biochemistry Serum 25(OH)D concentration were measured with the use of competitive enzyme-linked immunosorbent assay (ELISA: immunodiagnostic, Bernheim, Germany) after solid-phase extraction (reference range: 17-53 pg/mL). The intra- and interassay CVs for the 2 Vitamin D metabolites were <7,0% and 9,0%, respectively.

Statistical Analysis The data were analyzed with the SPSS version 21. The variables studied were described as frequencies, percentages and as median (interquartile range); inferential statistics were performed with non parametric tests (Mann Whitney and related sample Wilcoxon test), and correlations between variables were analyzed by bivariate correlation analysis by Pearson's correlation. Statistical significance was set at a p value < 0.05.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 45 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Effect of Vitamin D Supplementation on Blood Pressure in Elderly People
Study Start Date : April 2013
Actual Primary Completion Date : April 2013
Actual Study Completion Date : June 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Vitamin D

Arm Intervention/treatment
Active Comparator: Calcitriol
A daily dose of 1000 IU of cholecalciferol (administered as 1 capsule of 25 μg each)
Dietary Supplement: Calcitriol
Subjects whom were enrolled for 6 weeks of treatment with a daily dose of Calcitriol (1000 UI)

Placebo Comparator: Control
A daily dose of placebo (administered as 1 capsule )
Dietary Supplement: Control
Subjects whom were enrolled for 6 weeks of treatment with a daily dose of Placebo




Primary Outcome Measures :
  1. Difference of systolic and diastolic blood pressure [ Time Frame: 6 weeks ]
    Difference between systolic and diastolic blood pressure before and after treatment.


Secondary Outcome Measures :
  1. Difference of Serum 25-Hidroxyvitamin-D [ Time Frame: 6 weeks ]
    Difference between 25-Hidroxyvitamin-D before and after treatment.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   60 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Adults aged ≥ 60 years with essential hypertension.
  • Subjects on anti-hypertensive for more than 10 years and the dosages were unchanged during the study.

Exclusion Criteria:

  • Subjects who had been treated with vitamin D within the last three months.
  • None were on hormone replacement therapy.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02047799


Locations
Layout table for location information
Mexico
Facultad de Medicina-Universidad de Colima
Colima, Mexico, 28000
Sponsors and Collaborators
Universidad de Colima
Investigators
Layout table for investigator information
Principal Investigator: Jaime A Bricio Barrios
Study Director: Carmen A Sánchez Ramírez, MD, PhD Universidad de Colima
Study Chair: Alín J Palacios Fonseca, MS Universidad de Colima
Study Chair: Mario del-Toro Equihua, PhD Universidad de Colima

Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Universidad de Colima
ClinicalTrials.gov Identifier: NCT02047799     History of Changes
Other Study ID Numbers: SanchezC
First Posted: January 28, 2014    Key Record Dates
Last Update Posted: November 13, 2017
Last Verified: November 2017

Keywords provided by Universidad de Colima:
elderly people, high blood pressure, vitamin D.

Additional relevant MeSH terms:
Layout table for MeSH terms
Hypertension
Vitamin D
Vascular Diseases
Cardiovascular Diseases
Vitamins
Ergocalciferols
Calcitriol
Micronutrients
Nutrients
Growth Substances
Physiological Effects of Drugs
Bone Density Conservation Agents
Calcium-Regulating Hormones and Agents
Calcium Channel Agonists
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Vasoconstrictor Agents